Design Therapeutics, Inc. DSGN Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Increase (Decrease) in Accounts Payable and Other Operating Liabilities at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities?
- Design Therapeutics, Inc. (DSGN) reported increase (decrease) in accounts payable and other operating liabilities of -$2.51M in Q1 2026.
- How has Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities changed year-over-year?
- Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities decreased by 734.2% year-over-year, from -$301K to -$2.51M.
- What is the long-term trend for Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities?
- Over 2 years (2022 to 2025), Design Therapeutics, Inc.'s increase (decrease) in accounts payable and other operating liabilities has grown at a -8.9% compound annual growth rate (CAGR), from $5.4M to $4.49M.